← Back to Search

Schizophrenia for Schizophrenia

N/A
Recruiting
Led By Deepak C D'Souza, MD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one time within 4 weeks of screening
Awards & highlights

Summary

This trial will help researchers learn more about how cannabinoids receptors are related to various psychiatric disorders.

Eligible Conditions
  • Schizophrenia
  • Cannabis Dependence
  • Prodromal Psychosis
  • Alcoholism (Family History)
  • Healthy Controls
  • Opioid Use Disorder
  • Post-Traumatic Stress Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one time within 4 weeks of screening
This trial's timeline: 3 weeks for screening, Varies for treatment, and one time within 4 weeks of screening for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PET Imaging

Trial Design

7Treatment groups
Experimental Treatment
Group I: SchizophreniaExperimental Treatment1 Intervention
Patients diagnosed with schizophrenia both on medication and off medication
Group II: Prodrome for psychotic illnessExperimental Treatment1 Intervention
Not meeting full criteria for psychotic illness but exhibiting prodromal symptoms
Group III: PTSD-Post Traumatic Stress DisorderExperimental Treatment1 Intervention
Patients diagnosed with Post Traumatic Stress Disorder
Group IV: Opioid Use DisorderExperimental Treatment1 Intervention
Patients diagnosed with Opioid Use Disorder
Group V: Healthy VolunteersExperimental Treatment1 Intervention
Healthy volunteers with no current or past major medical or psychiatric history
Group VI: Family history of alcoholismExperimental Treatment1 Intervention
Healthy volunteers with a first degree relative with alcoholism
Group VII: Cannabis dependenceExperimental Treatment1 Intervention
Frequent users of cannabis
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
[11-C]OMAR
2016
N/A
~170

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,907 Previous Clinical Trials
3,018,949 Total Patients Enrolled
59 Trials studying Schizophrenia
3,919 Patients Enrolled for Schizophrenia
National Institute on Drug Abuse (NIDA)NIH
2,543 Previous Clinical Trials
3,249,276 Total Patients Enrolled
51 Trials studying Schizophrenia
5,282 Patients Enrolled for Schizophrenia
National Institute of Mental Health (NIMH)NIH
2,869 Previous Clinical Trials
2,777,436 Total Patients Enrolled
253 Trials studying Schizophrenia
89,824 Patients Enrolled for Schizophrenia
~1 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top